Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Expert Opinion on Drug Safety

• Publication date

  2015-03-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14740338.2015.1011619PMID 25652768
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.

  2014cited by this paper
• The role of the opioid system in alcohol dependence

  2014cited by this paper
• Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study

  2014cited by this paper
• Efficacy of As-Needed Nalmefene in Alcohol-Dependent Patients with at Least a High Drinking Risk Level: Results from a Subgroup Analysis of Two Randomized Controlled 6-Month Studies

  2013cited by this paper
• Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.

  2013cited by this paper
• A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.

  2013cited by this paper
• A Double-Blind, Placebo-Controlled Trial Assessing the Efficacy of Varenicline Tartrate for Alcohol Dependence

  2013cited by this paper
• Addiction is a Reward Deficit and Stress Surfeit Disorder

  2013cited by this paper
• Effect of Nalmefene 20 and 80 mg on the Corrected QT Interval and T-Wave Morphology

  2012cited by this paper
• Safety, tolerability, and feasibility of high‐dose naltrexone in alcohol dependence: an open‐label study

  2011cited by this paper
• Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.

  2011cited by this paper
• The size and burden of mental disorders and other disorders of the brain in Europe 2010.

  2011cited by this paper
• Efficacy and tolerability of naltrexone in the management of alcohol dependence.

  2010cited by this paper
• Initial preference for drinking goal in the treatment of alcohol problems: II. Treatment outcomes.

  2010cited by this paper
• Long-term opioid blockade and hedonic response: preliminary data from two open-label extension studies with extended-release naltrexone.

  2010cited by this paper
• Initial preference for drinking goal in the treatment of alcohol problems: I. Baseline differences between abstinence and non-abstinence groups.

  2010cited by this paper
• The core characteristics and nursing care activities in psychiatric intensive care units in Sweden.

  2008cited by this paper
• Acamprosate: Safety and Tolerability in the Treatment of Alcohol Dependence

  2008cited by this paper
• Recovery: an international perspective

  2008cited by this paper
• Minimal structures , generalized topologies , and ascending systems should not be studied without generalized uniformities

  2007cited by this paper
• Reduction in heavy drinking as a treatment outcome in alcohol dependence.

  2007cited by this paper
• Dynorphin and the pathophysiology of drug addiction.

  2007cited by this paper
• Topiramate for treating alcohol dependence: a randomized controlled trial.

  2007cited by this paper
• Alcoholism and suicidal behavior: a clinical overview

  2006cited by this paper
• The BRENDA Model: Integrating Psychosocial Treatment and Pharmacotherapy for the Treatment of Alcohol Use Disorders

  2006cited by this paper
• Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

  2006cited by this paper
• Nalmefene Induced Elevation in Serum Prolactin in Normal Human Volunteers: Partial Kappa Opioid Agonist Activity?

  2005cited by this paper
• Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders.

  2005cited by this paper
• Treatment gap in mental health care.

  2004cited by this paper
• Use of mental health services in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project

  2004cited by this paper
• The treatment gap in mental health care.

  2004cited by this paper
• A Multi-site Dose Ranging Study of Nalmefene in the Treatment of Alcohol Dependence

  2004cited by this paper
• Opioid Receptor Blockade Eliminates Mood Effects of Aerobic Gymnastics

  2002cited by this paper
• Opioid peptides and the control of human ingestive behaviour.

  2002cited by this paper
• Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling.

  2001cited by this paper
• Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revision) (DSM-IV-TR)

  2001cited by this paper
• INTERNATIONAL GUIDE FOR MONITORING ALCOHOL CONSUMPTION AND RELATED HARM

  2000cited by this paper
• Naltrexone vs. Nefazodone for Treatment of Alcohol Dependence: A Placebo-Controlled Trial

  2000cited by this paper
• Safety Issues Concerning the Use of Disulfiram in Treating Alcohol Dependence

  1999cited by this paper
• Opioid antagonists in the treatment of impulse-control disorders.

  1998cited by this paper
• The mini international neuropsychiatric interview

  1998cited by this paper
• Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence

  1997cited by this paper
• The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI

  1997cited by this paper
• Drinking goal selection in behavioral self-management treatment of chronic alcoholics.

  1997cited by this paper
• A Risk-Benefit Assessment of Naltrexone in the Treatment of Alcohol Dependence

  1996cited by this paper
• Timeline Follow-Back A Technique for Assessing Self-Reported Alcohol Consumption

  1992cited by this paper
• Opiate receptor blockade by naltrexone and mood state after acute physical activity.

  1992cited by this paper
• Naloxone inhibits oxytocin release at orgasm in man.

  1990cited by this paper
• High-dose naltrexone therapy and dietary counseling for obesity.

  1987cited by this paper
• Pain sensitivity, mood and plasma endocrine levels in man following long‐distance running: Effects of naloxone

  1984cited by this paper

• Nalmefene Hydrochloride: Potential Implications for Treating Alcohol and Opioid Use Disorder

  2024cites this paper
• Medications for treating alcohol use disorder: A narrative review.

  2023cites this paper
• Sex differences and the lack of effects of chemogenetic manipulation of pro-opiomelanocortin (POMC) neurons on alcohol consumption in male and female mice.

  2022cites this paper
• Alcohol Use Disorder: Neurobiology and Therapeutics

  2022cites this paper
• Safety and Persistence of Nalmefene Treatment for Alcohol Dependence. Results from Two Post-authorisation Safety Studies

  2021cites this paper
• Use of Nalmefene in Routine Practice: Results from a French Prospective Cohort Study and a National Database Analysis

  2021cites this paper
• Pharmacotherapies and personalized medicine for alcohol use disorder: a review.

  2020cites this paper
• Evidenced-Based Pharmacotherapies for Alcohol Use Disorder: Clinical Pearls.

  2020cites this paper
• Sleep and the Pharmacotherapy of Alcohol Use Disorder: Unfortunate Bedfellows. A Systematic Review With Meta-Analysis

  2019cites this paper
• The effects of nalmefene on emotion processing in alcohol use disorder - A randomized, controlled fMRI study.

  2019cites this paper
• Safety of nalmefene for the treatment of alcohol use disorder: an update

  2019cites this paper
• Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review

  2018cites this paper
• Severe central sleep apnoea associated with nalmefene: a case report

  2018cites this paper
• Endogenous Opiates and Behavior: 2015.

  2017cites this paper
• Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy.

  2016cites this paper
• Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence

  2016cites this paper
• Lipophilic nalmefene prodrugs to achieve a one-month sustained release.

  2016cites this paper
• Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential

  2016cites this paper
• Pharmacological treatments for alcohol dependence 1 SAFETY AND TOLERABILITY OF PHARMACOLOGICAL TREATMENT OF ALCOHOL DEPENDENCE : COMPREHENSIVE REVIEW OF EVIDENCE

  2016cites this paper
• Pharmacological Treatment Options for Alcohol Use Disorder

  2015cites this paper
• *Abridged version of the "Therapeutic Guideline for Alcohol Use Disorder" prepared by the Working Group Therapeutic Guideline for Alcohol Use Disorder.

  2015cites this paper
• Evidence-Based Pharmacotherapies for Alcohol Use Disorder: Clinical Pearls

  year unknowncites this paper